HeimB1MR34 • BVMF
add
Biomarin Pharmaceutical Inc Bdr
Við síðustu lokun
160,17 R$
Dagbil
160,17 R$ - 160,17 R$
Árabil
139,16 R$ - 208,72 R$
Markaðsvirði
11,87 ma. USD
Meðalmagn
251,00
V/H-hlutf.
-
A/V-hlutfall
-
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | des. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 874,56 m. | 17,03% |
Rekstrarkostnaður | 209,05 m. | -21,53% |
Nettótekjur | -46,57 m. | -137,28% |
Hagnaðarhlutfall | -5,33 | -131,88% |
Hagnaður á hvern hlut | 0,46 | -50,00% |
EBITDA | 217,83 m. | 11,79% |
Virkt skatthlutfall | -71,52% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | des. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 1,56 ma. | 37,17% |
Heildareignir | 7,59 ma. | 8,66% |
Heildarskuldir | 1,51 ma. | 13,23% |
Eigið fé alls | 6,09 ma. | — |
Útistandandi hlutabréf | 192,30 m. | — |
Eiginfjárgengi | 5,06 | — |
Arðsemi eigna | 6,49% | — |
Ávöxtun eigin fjár | 7,40% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | des. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -46,57 m. | -137,28% |
Handbært fé frá rekstri | 99,64 m. | -46,32% |
Reiðufé frá fjárfestingum | -42,45 m. | -155,56% |
Reiðufé frá fjármögnun | 3,16 m. | 10,42% |
Breyting á handbæru fé | 61,57 m. | -76,97% |
Frjálst peningaflæði | 97,97 m. | 16,80% |
Um
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Framkvæmdastjóri
Stofnsett
mar. 1997
Höfuðstöðvar
Vefsvæði
Starfsfólk
3.221
